Osimertinib belongs to the first generation of targeted drugs

Osimertinib (Osimertinib) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It is currently designated as a first-line treatment for non-small cell lung cancer (NSCLC) and patients sensitized by EGFR mutations; as a second-line treatment for patients with resistance-related mutation T790M after previous EGFR-TKIs treatment; and as an adjuvant treatment for patients with early resection of non-small cell lung cancer with EGFR mutations.

Compared with the first and second generation EGFR inhibitors, osimertinib has higher selectivity and anti-tumor activity, and can more effectively inhibit the growth and spread of EGFR mutation-positive lung cancer cells, including EGFRexon 19 deletion or exon 21 L858R mutation. At the same time, the side effects of osimertinib are relatively mild and are easier for patients to tolerate. Common side effects include diarrhea, rash, musculoskeletal pain, nail poisoning, dry skin, stomatitis, fatigue and cough. Therefore, osimertinib has good efficacy and safety in the treatment of non-small cell lung cancer.

OsimertinibThe original drug has been launched in China and has been covered by medical insurance. The price of 80mg*30 tablets per box may be around 5,000 yuan, which is relatively expensive. Currently available overseas Osimertinib generics, such as the specifications produced by Bangladesh Pharmaceutical FactoryThe price of each box of 80mg*30 tablets may be more than 800 yuan (the price may fluctuate due to exchange rate effects), which is relatively cheap. Osimertinib generics have basically the same pharmaceutical ingredients as the original drugs sold domestically and abroad. For more drug information and specific prices, please consult Yaode Medical Consultant.